Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NIH's Zika Vaccine Faces Funding Challenge After Skipping Industry Partnership

Executive Summary

Agency wanted to move fast, but is now scrambling to pay for Phases I and II trials.

Advertisement

Related Content

Zika Vaccines Might Be Approved By 2020
Zika Vaccine Trials Could Test Multiple Candidates Vs. Common Control Group
Public Health Funding Faces Grim Prospects Before, After Election
Pediatric Rare Disease Voucher Program Faces Expiration
Playing the Long Game, Partnerships Required For Emerging Infectious Diseases
Feds Closer To Dx Distinguishing Zika From Dengue As HHS Tries To Plug Funding Gap
GSK/NIH 'SAM' Strategy May Reap Benefits Beyond Zika
Sanofi Teams With US Military On Zika, But Not For The Profits
Robbing Ebola To Pay For Zika: Playing With Fire?

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS118969

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel